The role of DNA damage and repair in atherosclerosis: A review

Journal of Molecular and Cellular Cardiology

Volumn 86, Issue , 2015, Pages 147-157

  Shah, Nikunj R ^a   Mahmoudi, Michael ^a,b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b ST PETER S HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Deoxyribonucleic acid; Repair enzymes

Indexed keywords

ANTIOXIDANT; ATM PROTEIN; ATR PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVONOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; MICRORNA; MRE11 PROTEIN; NIBRIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; RAD50 PROTEIN; REACTIVE OXYGEN METABOLITE; SIRTUIN 1; SIRTUIN 3; SIRTUIN 6; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHROMOSOME ABERRATION; CHRONIC INFLAMMATION; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA ADDUCT; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DRUG MECHANISM; EXCISION REPAIR; HEART PROTECTION; HOMOLOGOUS RECOMBINATION; HUMAN; MISMATCH REPAIR; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TELOMERE SHORTENING; THERAPY EFFECT; ATHEROSCLEROTIC PLAQUE; GENETICS; PATHOLOGY;

ATHEROSCLEROSIS; DNA DAMAGE; DNA REPAIR; HUMANS; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; SIGNAL TRANSDUCTION;

EID: 84938696803     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.07.005     Document Type: Review

References (189)

1. Global Status Report on Non-Communicable Diseases 2010 2011, World Health Organization, Geneva.
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362(6423):801-809.
3. Licastro F., et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun. Ageing 2005, 2:8.
4. Botto N., Rizza A., Colombo M.G., Mazzone A.M., Manfredi S., Masetti S., et al. Evidence for DNA damage in patients with coronary artery disease. Mutat. Res. 2001, 493(1-2):23-30.
5. Demirbag R., Yilmaz R., Kocyigit A. Relationship between DNA damage, total antioxidant capacity and coronary artery disease. Mutat. Res. 2005, 570(2):197-203.
6. Andreassi M.G. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutat. Res. 2003, 543:67-86.
7. Andreassi M.G., Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc. Med. 2003, 13:270-275.
8. Mahmoudi M., Mercer J., Bennett M. DNA damage and repair in atherosclerosis. Cardiovasc. Res. 2006, 71:259-268.
9. Demirbag R., Yilmaz R., Gur M., Kocyigit A., Celik H., Guzel S., et al. Lymphocyte DNA damage in patients with acute coronary syndrome and its relationship with severity of acute coronary syndrome. Mutat. Res. 2005, 578(1-2):298-307.
10. Simon A.S., Chithra V., Vijayan A., Dinbesh R.D., Vijayakumar T. Altered DNA repair, oxidative stress and antioxidant status in coronary artery disease. J. Biosc. 2013, 38(2):385-389.
11. Hatzistamou J., Kiaris H., Ergazaki M., Spandidos D.A. Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem. Biophys. Res. Commun. 1996, 225:186-190.
12. Matturri L., Cazzullo A., Turconi P., Lavezzi A.M. Cytogenetic aspects of cell proliferation in atherosclerotic plaques. Cardiologica 1997, 42:833-836.
13. Casalone R., Granata P., Minelli E., Portentoso P., Giudici A., Righi R., et al. Cytogenetic analysis reveals clonal proliferation of smooth muscle cells in atherosclerotic plaques. Hum. Genet. 1991, 87:139-143.
14. Binkova B., Smerhovsky Z., Strejc P., Boubelik O., Stavkova Z., Chvatalova I., et al. DNA adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat. Res. 2002, 501:115-128.
15. De Flora S., Izzotti A., Walsh D., Degan P., Petrilli G.L., Lewtas J. Molecular epidemiology of atherosclerosis. FASEB J. 1997, 11:1021-1031.
16. Basta G., Schmidt A.M., De Caterina R. Advanced glycation products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 2004, 63:582-592.
17. Botto N., Masetti S., Petrozzi L., Vassalle C., Manfredi S., Biagini A., et al. Elevated levels of oxidative DNA damage in patients with coronary artery disease. Coron. Artery Dis. 2002, 13:269-274.
18. Martinet W., Knaapen M., De Meyer G., Herman A., Kockx M. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 2002, 106:927-932.
19. Kunsch C., Medford R.M. Oxidative stress as a regulator of gene expression in the vasculature. Circ. Res. 1999, 85:753-766.
20. Irani K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 2000, 87:179-183.
21. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., et al. Mitochondrial integrity and function in atherogenesis. Circulation 2002, 106:544-549.
22. Sugamura K., Keaney J.F. Reactive oxygen species in cardiovascular disease. Free Radic. Biol. Med. 2011, 51(5):978-992.
23. Vivekananthan D.P., Penn M.S., Sapp S.K., Hsu A., Topol E.J. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003, 14: 361(9374):2017-2023.
24. Tardif J.C., McMurray J.J., Klug E., Small R., Schumi J., Choi J., et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371(9626):1761-1768.
25. Rapola J.M., Virtamo J., Ripatti S., Haukka J.K., Huttunen J.K., Albanes D., et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris. Heart 1998, 79:454-458.
26. Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005, 25:29-38.
27. Yu E., Calvert P.A., Mercer J.R., Harrison J., Baker L., Figg N.L., et al. Mitochondrial DNA damage can promote atherosclerosis independently of reactive oxygen species through effects on smooth muscle cells and monocytes and correlates with higher-risk plaques in humans. Circulation 2013, 128:702-712.
28. Botto N., Berti S., Manfredi S., Al-Jabri A., Federici C., Clerico A., et al. Detection of mtDNA with 4977bp deletion in blood cells and atherosclerotic lesions of patients with coronary artery disease. Mutat. Res. 2005, 570(1):81-88.
29. Ding Z., Liu S., Wang X., Khaidakov M., Dai Y., Mehta J.L. Oxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis. Sci. Rep. 2013, 3:1077.
30. Edo M.D., Andrés V. Aging, telomeres, and atherosclerosis. Cardiovasc. Res. 2005, 66(2):213-221.
31. Salpea K.D., Talmud P.J., Cooper J.A., Maubaret C.G., Stephens J.W., Abelak K., Humphries S.E. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis 2010, 209(1):42-50.
32. Willeit P., Willeit J., Brandstätter A., Ehrlenbach S., Mayr A., Gasperi A., et al. Cellular aging reflected by leukocyte telomere length predicts advanced atherosclerosis and cardiovascular disease risk. Arterioscler. Thromb. Vasc. Biol. 2010, 30(8):1649-1656.
33. Brouilette S.W., Moore J.S., McMahon A.D., Thompson J.R., Ford I., Shepherd J., et al. Telomere length, risk of coronary disease and statin treatment in the West of Scotland Primary Prevention Study: a nested case-control study. Lancet 2007, 369:107-114.
34. Farzaneh-Far R., Cawthon R., Na B., Browner W.S., Schiller N.B., Whooley M.A. Prognostic value of leucocyte telomere length in patients with stable coronary artery disease. Data from the Heart and Soul Study. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1379-1384.
35. Zhu H., Belcher M., van der Harst P. Healthy aging and disease: role for telomere biology?. Clin. Sci. (Lond.) 2011, 120(10):427-440.
36. Paul L. Diet, nutrition and telomere length. J. Nutr. Biochem. 2011, 22(10):895-901.
37. Saliques S., Teyssier J.R., Vergely C., Lorgis L., Lorin J., Farnier M., et al. Circulating leukocyte telomere length and oxidative stress: a new target for statin therapy. Atherosclerosis 2011, 219(2):753-760.
38. Federici C., Drake K.M., Rigelsky C.M., McNelly L.N., Meade S.L., Comhair S.A., et al. Increased mutagen sensitivity and DNA Damage in pulmonary arterial hypertension. Am J Respir Crit Care Med 2015, 192(2):219-228.
39. Wang J.C., Bennett M. Mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ. Res. 2012, 111:245-259.
40. Libby P. Inflammation in atherosclerosis. Nature 2002, 420(6917):868-874.
41. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11(2):85-97.
42. Ahima R.S., Flier J.S. Adipose tissue as an endocrine organ. Trends Endocrinol. Metab. 2000, 11:327-332.
43. Zhang H., Cui J., Zhang C. Emerging role of adipokines as mediators in atherosclerosis. World J. Cardiol. 2010, 2(11):370-376.
44. Schuett H., Luchtefeld M., Grothusen C., Grote K., Schieffer B. How much is too much? Interleukin-6 and its signaling in atherosclerosis. Thromb. Haemost. 2009, 102:215-222.
45. Lyon C.J., Law R.E., Hsueh W.A. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003, 144:2195-2200.
46. Chen X., Andresen B.T., Hill M., Zhang J., Booth F., Zhang C. Role of reactive oxygen species in tumor necrosis factor-alpha induced endothelial dysfunction. Curr. Hypertens. Rev. 2008, 4(4):245-255.
47. Zhang L., Peppel K., Sivashanmugam P., Orman E.S., Brian L., Exum S.T., et al. Expression of tumor necrosis factor receptor-1 in arterial wall cells promotes atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2007, 27(5):1087-1094.
48. Brånén L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2137-2142.
49. Okamoto Y., Kihara S., Ouchi N., Nishida M., Arita Y., Kumada M., et al. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 2002, 106(22):2767-2770.
50. Goldstein B.J., Scalia R.G., Ma X.L. Protective vascular and myocardial effects of adiponectin. Nat. Clin. Pract. Cardiovasc. Med. 2009, 6(1):27-35.
51. Tao L., Gao E., Jiao X., Yuan Y., Li S., Christopher T.A., et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 2007, 115(11):1408-1416.
52. Roubille C., Richer V., Starnino T., McCourt C., McFarlane A., Fleming P., et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 2015, 74(3):480-489.
53. Mäki-Petäjä K.M., Elkhawad M., Cheriyan J., Joshi F.R., Ostör A.J., Hall F.C., et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation 2012, 126(21):2473-2480.
54. Solomon D.H., Curtis J.R., Saag K.G., Lii J., Chen L., Harrold L.R., et al. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am. J. Med. 2013, 126(8):730.e9-730.e17.
55. Durik M., Kavousi M., van der Pluijm I., Isaacs A., Cheng C., Verdonk K., et al. Nucleotide excision DNA repair is associated with age-related vascular dysfunction. Circulation 2012, 126:468-478.
56. Jeon B.H., Gupta G., Park Y.C., Qi B., Haile A., Khanday F.A., et al. Apurinic/apyrimidinic endonuclease 1 regulates endothelial NO production and vascular tone. Circ. Res. 2004, 95:902-910.
57. Bohgaki T., Bohgaki M., Hakem R. DNA double-strand break signaling and human disorders. Genome Integr. 2010, 1(1):15.
58. Cooke M.S., Evans M.D., Dizdaroglu M., Lunec J. Oxidative DNA damage: mechanisms, mutation, and disease. FASEB J. 2003, 17(10):1195-1214.
59. Lieber M.R. The mechanism of human non-homologous DNA end joining. J. Biol. Chem. 2008, 283:1-5.
60. Hopkins B.B., Paull T.T. The P. furiosus Mre11/Rad50 complex promotes 5' strand resection at a DNA double-strand break. Cell 2008, 135(2):250-260.
61. Paull T.T., Gellert M. NBS1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. Genes Dev. 1999, 13:1276-1288.
62. van der Linden E., Sanchez H., Kinoshita E., Kanaar R., Wyman C. RAD50 and NBS1 form a stable complex functional in DNA binding and tethering. Nucleic Acids Res. 2009, 37:1580-1588.
63. Hopfner K.-P., Craig L., Moncalian G., Zinkel R.A., Usui T., Owen B.A.L., et al. The Rad50 zinc-hook is a structure joining Mre11 complexes in DNA recombination and repair. Nature 2002, 418:562-566.
64. Williams R.S., Dodson G.E., Limbo O., Yamada Y., Williams J.S., Guenther G., et al. NBS1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate DNA double-strand break processing and repair. Cell 2009, 139(1):87-99.
65. Nijmegen breakage syndrome. The International Nijmegen Breakage Syndrome Study Group. Arch. Dis. Child. 2000, 82(5):400-406.
66. Gray K., Kumar S., Figg N., Harrison J., Baker L., Mercer J., et al. Effects of DNA damage in smooth muscle cells in atherosclerosis. Circ. Res. 2015, 116(5):816-826.
67. Venclovas C., Thelen M. Structure-based predictions of Rad1, Rad9, Hus1, and Rad17 participation in sliding clamp and clamp-loading complexes. Nucleic Acids Res. 2000, 28:2481-2493.
68. Bermudez V.P., Lindsey-Boltz L.A., Cesare A.J., Maniwa Y., Griffith J.D., Hurwitz J., et al. Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(4):1633-1638.
69. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 461:1071-1078.
70. Michishita E., Park J.Y., Burneskis J.M., Barrett J.C., Horikawa I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell 2005, 16(10):4623-4635.
71. Wang C., Chen L., Hou X., Li Z., Kabra N., Ma Y., et al. Interactions between E2F1 and SIRT1 regulate apoptotic response to DNA damage. Nat. Cell Biol. 2006, 8:1025-1031.
72. Zhang Q.J., Wang Z., Chen H.Z., Zhou S., Zheng W., Liu G., et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc. Res. 2008, 80(2):191-199.
73. Mattagajasingh I., Kim C.S., Naqvi A., Yamamori T., Hoffman T.A., Jung S.B., et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14855-14860.
74. Li X., Zhang S., Blander G., Tse J.G., Krieger M., Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 2007, 28:91-106.
75. Nakamaru Y., Vuppusetty C., Wada H., Milne J.C., Ito M., Rossios C., et al. A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9. FASEB J. 2009, 9:2810-2819.
76. Cardellini M., Menghini R., Martelli E., Casagrande V., Marino A., Rizza S., et al. TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SIRT1. Diabetes 2009, 58:2396-2401.
77. Gorenne I., Kumar S., Gray K., Figg N., Yu H., Mercer J., Bennett M. Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis. Circulation 2013, 127(3):386-396.
78. Alcendor R.R., Gao S., Zhai P., Zablocki D., Holle E., Yu X., et al. Sirt1 regulates ageing and resistance to oxidative stress in the heart. Circ. Res. 2007, 100:1512-1521.
79. Sundaresan N.R., Gupta M., Kim G., Rajamohan S.B., Isbatan A., Gupta M.P. SIRT3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 2009, 119:2758-2771.
80. Winnik S., Gaul D.S., Preitner F., Lohmann C., Weber J., Miranda M.X., et al. Deletion of Sirt3 does not affect atherosclerosis but accelerates weight gain and impairs rapid metabolic adaptation in LDL receptor knockout mice: implications for cardiovascular risk factor development. Basic Res. Cardiol. 2014, 109(1):399.
81. Cardus A., Uryga A.K., Walters G., Erusalimsky J.D. SIRT6 protects human endothelial cells from DNA damage, telomere dysfunction, and senescence. Cardiovasc. Res. 2013, 97:571-579.
82. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 2010, 108:73-112.
83. Swift M., Heim R.A., Lench N.J. Genetic aspects of ataxia-telangiectasia. Adv. Neurol. 1993, 61:115-125.
84. Swift M., Chase C. Cancer and cardiac deaths in obligatory ataxia-telangiectasia mutant alleles. Lancet 1983, 1:1049-1050.
85. Smirnov D.A., Cheung V.G. ATM gene mutations result in both recessive and dominant expression phenotypes of genes and microRNAs. Am. J. Hum. Genet. 2008, 83(2):243-253.
86. Mercer J.R., Cheng K.K., Figg N., Gorenne I., Mahmoudi M., Griffin J., et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ. Res. 2010, 107:1021-1031.
87. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421(6922):499-506.
88. Andegeko Y., Moyal L., Mittelman L., Tsarfaty I., Shiloh Y., Rotman G. Nuclear retention of ATM at sites of DNA double strand breaks. J. Biol. Chem. 2001, 276:38224-38230.
89. Kurz E.U., Lees-Miller S.P. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004, 3(8-9):889-900.
90. Abraham R. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15:2177-2196.
91. Morrison C., Sonoda E., Takao N., Shinohara A., Yamamoto K., Takeda S. The controlling role of ATM in homologous recombinational repair of DNA damage. EMBO J. 2000, 19:463-471.
92. Brown E.J., Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev. 2000, 14(4):397-402.
93. Mohni K.N., Kavanaugh G.M., Cortez D. ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency. Cancer Res. 2014, 74(10):2835-2845.
94. Patil M., Pabla N., Dong Z. Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell. Mol. Life Sci. 2013, 70(21):4009-4021.
95. Liu S., Bekker-Jensen S., Mailand N., Lukas C., Bartek J., Lukas J. Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Mol. Cell. Biol. 2006, 26(16):6056-6064.
96. Lukas C., Falck J., Bartkova J., Bartek J., Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat. Cell Biol. 2003, 5(3):255-260.
97. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R., Hurov K.E., Luo J., et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007, 316:1160-1166.
98. Ahn J.Y., Schwarz J.K., Piwnica-Worms H., Canman C.E. Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation. Cancer Res. 2000, 60(21):5934-5936.
99. Zannini L., Delia D., Buscemi G. CHK2 kinase in the DNA damage response and beyond. J Mol Cell Biol. 2014, 6:442-457.
100. Chaturvedi P., Eng W.K., Zhu Y., Mattern M.R., Mishra R., Hurle M.R., et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 1999, 18(28):4047-4054.
101. Chehab N.H., Malikzay A., Appel M., Halazonetis T.D. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev. 2000, 14:278-288.
102. Chen L., Gilkes D.M., Pan Y., Lane W.S., Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005, 24:3411-3422.
103. Tan Y., Raychaudhuri P., Costa R.H. Chk2 mediates stabilization of the FOXM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell. Biol. 2007, 27:1007-1016.
104. Schutte M., Seal S., Barfoot R., Meijers-Heijboer H., Wasielewski M., Evans D.G., et al. Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am. J. Hum. Genet. 2003, 72:1023-1028.
105. Bell D.W., Varley J.M., Szydlo T.E., Kang D.H., Wahrer D.C., Shannon K.E., et al. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science 1999, 286(5449):2528-2531.
106. deLaat W.L., Jaspers N.G., Hoeijmakers J.H. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999, 13(7):768-785.
107. Muendlein A., Saely C.H., Geller-Rhomberg S., Sonderegger G., Rein P., Winder T., et al. Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis. PLoS ONE 2011, 6(3):e17978.
108. Morrison A.C., Bare L.A., May M.M., Pankow J.S., Mosley T.H., Devlin J.J., et al. Single nucleotide polymorphisms associated with coronary heart disease predict incident ischaemic stroke in the Atherosclerosis Risk in Communities (ARIC) study. Cerebrovasc. Dis. 2008, 26(4):420-424.
109. Helgadottir A., Thorleifsson G., Magnusson K.P., Grétarsdottir S., Steinthorsdottir V., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat. Genet. 2008, 40(2):217-224.
110. Helgadottir A., Thorleifsson G., Manolescu A., Gretarsdottir S., Blondal T., Jonasdottir A., et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science 2007, 316(5830):1491-1493.
111. Motterle A., Pu X., Wood H., Xiao Q., Gor S., Liang Ng F., Chan K., Cross F., et al. Functional analyses of coronary artery disease associated variation on chromosome 9p21 in vascular smooth muscle cells. Hum. Mol. Genet. 2012, 21(18):4021-4029.
112. Liu Y., Prasad R., Beard W.A., Kedar P.S., Hou E.W., Shock D.D., Wilson S.H. Coordination of steps in single-nucleotide base excision repair mediated by apurinic/apyrimidinic endonuclease 1 and DNA polymerase β. J. Biol. Chem. 2007, 282(18):13532-13541.
113. Rice P.A. Holding damaged DNA together. Nat. Struct. Biol. 1999, 6(9):805-806.
114. Schreiber V., Dantzer F., Ame J.C., de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat. Rev. Mol. Cell Biol. 2006, 7:517-528.
115. Krishnakumar R., Kraus W.L. The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol. Cell 2010, 39:8-24.
116. Pacher P., Szabó C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev. 2007, 25(3):235-260.
117. Kassan M., Choi S.K., Galán M., Bishop A., Umezawa K., Trebak M., et al. Enhanced NF-κB activity impairs vascular function through PARP-1-, SP-1-, and COX-2-dependent mechanisms in type 2 diabetes. Diabetes 2013, 62(6):2078-2087.
118. Radovits T., Lin L.N., Zotkina J., Gero D., Szabó C., Karck M., et al. Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro. Eur. J. Pharmacol. 2007, 564(1-3):158-166.
119. Hans C.P., Feng Y., Naura A.S., Zerfaoui M., Rezk B.M., Xia H., et al. Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress. PLoS One 2009, 4(10):e7430.
120. Morrow D.A., Brickman C.M., Murphy S.A., Baran K., Krakover R., Dauerman H., et al. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis 2009, 27(4):359-364.
121. Meloche J., Pflieger A., Vaillancourt M., Paulin R., Potus F., Zervopoulos S., et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 2014, 129:786-797.
122. Courboulin A., Paulin R., Giguère N.J., Saksouk N., Perreault T., Meloche J., et al. Role for miR-204 in human pulmonary arterial hypertension. J. Exp. Med. 2011, 208(3):535-548.
123. Bonnet S., Paulin R., Sutendra G., Dromparis P., Roy M., Watson K.O., et al. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 2009, 120(13):1231-1240.
124. Zetterqvist A.V., Berglund L.M., Blanco F., Garcia-Vaz E., Wigren M., Dunér P., et al. Inhibition of nuclear factor of activated T-cells (NFAT) suppresses accelerated atherosclerosis in diabetic mice. PLoS One 2013, 8(6):e65020.
125. Lambert C.M., Roy M., Robitaille G.A., Richard D.E., Bonnet S. HIF-1 inhibition decreases systemic vascular remodelling diseases by promoting apoptosis through a hexokinase 2-dependent mechanism. Cardiovasc. Res. 2010, 88(1):196-204.
126. Vink A., Schoneveld A.H., Lamers D., Houben A.J., van der Groep P., van Diest P.J., et al. HIF-1 alpha expression is associated with an atheromatous inflammatory plaque phenotype and upregulated in activated macrophages. Atherosclerosis 2007, 195(2):e69-e75.
127. Erbel C., Achenbach J., Akhavanpoor M., Dengler T.J., Lasitschka F., Gleissner C.A., et al. PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels. Eur. J. Med. Res. 2011, 16(8):367-374.
128. Rajamohan S.B., Pillai V.B., Gupta M., Sundaresan N.R., Birukov K.G., Samant S., et al. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol. Cell. Biol. 2009, 29:4116-4129.
129. Bai P., Canto C., Oudart H., Brunyanszki A., Cen Y., Thomas C., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011, 13(4):461-468.
130. Kolthur Seetharam U., Dantzer F., Mcburney M.W., Murcia G.D., Sassone-corsi P. Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle 2006, 5(8):873-877.
131. Luna A., Aladjem M.I., Kohn K.W. SIRT1/PARP1 crosstalk: connecting DNA damage and metabolism. Genome Integr. 2013, 4:6.
132. Xu S., Bai P., Little P.J., Liu P. Poly(ADP-ribose) polymerase 1 (PARP1) in atherosclerosis: from molecular mechanisms to therapeutic implications. Med. Res. Rev. 2014, 34(3):644-675.
133. Bazo A.P., Salvadori D., Salvadori R.A., Sodré L.P., da Silva G.N., de Camargo E.A., et al. DNA repair gene polymorphism is associated with the genetic basis of atherosclerotic coronary artery disease. Cardiovasc. Pathol. 2011, 20(1):e9-e15.
134. Guven M., Guven G.S., Oz E., Ozaydin A., Batar B., Ulutin T., et al. DNA repair gene XRCC1 and XPD polymorphisms and their association with coronary artery disease risks and micronucleus frequency. Heart Vessel. 2007, 22(6):355-360.
135. Skarpengland T., Laugsand L.E., Janszky I., Luna L., Halvorsen B., Platou C.G., et al. Genetic variants in the DNA repair gene NEIL3 and the risk of myocardial infarction in a nested case-control study. The HUNT study. DNA Repair (Amst) 2015, 28:21-27.
136. Verschuren J.J., Trompet S., Deelen J., Stott D.J., Sattar N., Buckley B.M., et al. Non-homologous end-joining pathway associated with occurrence of myocardial infarction: gene set analysis of genome-wide association study data. PLoS One 2013, 8(2):e56262.
137. Larrea A.A., Lujan S.A., Kunkel T.A. DNA mismatch repair. Cell 2010, 141(4):730.
138. Flouris G.A., Arvanitis D.A., Parissis J.T., Arvanitis D.L., Spandidos D.A. Loss of heterozygosity in DNA mismatch repair genes in human atherosclerotic plaques. Mol. Cell Biol. Res. Commun. 2000, 4(1):62-65.
139. Grati F.R., Ghilardi G., Sirchia S.M., Massaro F., Cassani B., Scorza R., et al. Loss of heterozygosity of the NOS3 dinucleotide repeat marker in atherosclerotic plaques of human carotid arteries. Atherosclerosis 2001, 159(2):261-267.
140. Miniati P., Sourvinos G., Michalodimitrakis M., Spandidos D.A. Loss of heterozygosity on chromosomes 1, 2, 8, 9 and 17 in cerebral atherosclerotic plaques. Int. J. Biol. Markers 2001, 16(3):167-171.
141. Albinsson S., Suarez Y., Skoura A., Offermanns S., Miano J.M., Sessa W.C. MicroRNA are necessary for vascular smooth muscle growth, differentiation, and function. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1118-1126.
142. Bartel D.P. MicroRNA: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
143. Albinsson S., Sessa W.C. Can microRNA control vascular smooth muscle phenotypic modulation and the response to injury?. Physiol. Genomics 2011, 43:529-533.
144. Chen W.J., Yin K., Zhao G.J., Fu Y.C., Tang C.K. The magic and mystery of microRNA-27 in atherosclerosis. Atherosclerosis 2012, 222(2):314-323.
145. Sacco J., Adeli K. MicroRNAs: emerging roles in lipid and lipoprotein metabolism. Curr. Opin. Lipidol. 2012, 23(3):220-225.
146. Suárez Y., Wang C., Manes T.D., Pober J.S. Cutting edge: TNF-induced microRNAs regulate TNF-induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J. Immunol. 2010, 184(1):21-25.
147. Asgeirsdóttir S.A., van Solingen C., Kurniati N.F., Zwiers P.J., Heeringa P., van Meurs M., et al. MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am. J. Physiol. Ren. Physiol. 2012, 302(12):F1630-F1639.
148. Fang Y., Shi C., Manduchi E., Civelek M., Davies P.F. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(30):13450-13455.
149. Sun X., Icli B., Wara A.K., Belkin N., He S., Kobzik L., et al. MicroRNA-181b regulates NF-κB-mediated vascular inflammation. J. Clin. Invest. 2012, 122(6):1973-1990.
150. Nazari-Jahantigh M., Wei Y., Noels H., Akhtar S., Zhou Z., Koenen R.R., et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 2012, 122(11):4190-4202.
151. Chen T., Huang Z., Wang L., Wang Y., Wu F., Meng S., et al. MicroRNA-125a-5p partly regulates the inflammatory response, lipid uptake, and ORP9 expression in oxLDL-stimulated monocyte/macrophages. Cardiovasc. Res. 2009, 83(1):131-139.
152. Ikeda S., Kong S.W., Lu J., Bisping E., Zhang H., Allen P.D., et al. Altered microRNA expression in human heart disease. Physiol. Genomics 2007, 31(3):367-373.
153. Lovren F., Pan Y., Quan A., Singh K.K., Shukla P.C., Gupta N., et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012, 126(11 Suppl 1):S81-S90.
154. Loyer X., Mallat Z., Boulanger C.M., Tedgui A. MicroRNAs as therapeutic targets in atherosclerosis. Expert Opin. Ther. Targets 2015, 19(4):489-496.
155. Bazzano L.A., He J., Ogden L.G., Loria C.M., Vupputuri S., Myers L., et al. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am. J. Clin. Nutr. 2002, 76(1):93-99.
156. Joshipura K.J., Hu F.B., Manson J.E., Stampfer M.J., Rimm E.B., Speizer F.E., et al. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann. Intern. Med. 2001, 134(12):1106-1114.
157. Liu S., Manson J.E., Lee I.M., Cole S.R., Hennekens C.H., Willett W.C., et al. Fruit and vegetable intake and risk of cardiovascular disease: the Women's Health Study. Am. J. Clin. Nutr. 2000, 72(4):922-928.
158. Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr. Rev. 1998, 56(11):317-333.
159. Hertog M.G., Feskens E.J., Hollman P.C., Katan M.B., Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993, 342(8878):1007-1011.
160. Hertog M.G., Kromhout D., Aravanis C., Blackburn H., Buzina R., Fidanza F., et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study. Arch. Intern. Med. 1995, 155(4):381-386.
161. Knekt P., Jarvinen R., Reunanen A., Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996, 312(7029):478-481.
162. Yochum L., Kushi L.H., Meyer K., Folsom A.R. Dietary flavonoid intake and risk of cardiovascular disease in postmenopausal women. Am. J. Epidemiol. 1999, 149(10):943-949.
163. Siasos G., Tousoulis D., Tsigkou V., Kokkou E., Oikonomou E., Vavuranakis M., et al. Flavonoids in atherosclerosis: an overview of their mechanisms of action. Curr. Med. Chem. 2013, 20(21):2641-2660.
164. Dietrich M., Jacques P.F., Pencina M.J., Lanier K., Keyes M.J., Kaur G., et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart study: does the underlying health status play a role?. Atherosclerosis 2009, 205:549-553.
165. Bleys J., Miller E.R., Pastor-Barriuso R., Appel L.J., Guallar E. Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2006, 84:880-887. [quiz 954-5].
166. Katsiki N., Manes C. Is there a role for supplemented antioxidants in the prevention of atherosclerosis?. Clin. Nutr. 2009, 28:3-9.
167. Miller E.R., Juraschek S., Pastor-Barriuso R., Bazzano L.A., Appel L.J., Guallar E. Meta-analysis of folic acid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels. Am. J. Cardiol. 2010, 106:517-527.
168. Ravn-Haren G., Bugel S., Krath B.N., Hoac T., Stagsted J., Jorgensen K., et al. A short term intervention trial with selenate, selenium-enriched yeast and selenium-enriched milk: effects on oxidative defence regulation. Br. J. Nutr. 2008, 99:883-892.
169. Rippe C., Lesniewski L., Connell M., LaRocca T., Donato A., Seals D. Short-term calorie restriction reverses vascular endothelial dysfunction in old mice by increasing nitric oxide and reducing oxidative stress. Aging Cell 2010, 9:304-312.
170. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab. 2008, 8(2):157-168.
171. Tomé-Carneiro J., Gonzálvez M., Larrosa M., Yáñez-Gascón M.J., García-Almagro F.J., Ruiz-Ros J.A., et al. Resveratrol in primary and secondary prevention of cardiovascular disease: a dietary and clinical perspective. Ann. N. Y. Acad. Sci. 2013, 1290:37-51.
172. Liu Y., Ma W., Zhang P., He S., Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin. Nutr. 2015, 34(1):27-34.
173. Kwok J.M., Ma C.C., Ma S. Recent development in the effects of statins on cardiovascular disease through Rac1 and NADPH oxidase. Vasc. Pharmacol. 2013, 58(1-2):21-30.
174. Lefer A.M., Scalia R., Lefer D.J. Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease. Cardiovasc. Res. 2001, 49(2):281-287.
175. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., Bäumeret A.T., et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler. Thromb. Vasc. Biol. 2002, 22:300-305.
176. Girona J., La Ville A.E., Solà R., Plana N., Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am. J. Cardiol. 1999, 83(6):846-851.
177. Yamamoto A., Hoshi K., Ichihara K. Fluvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-CoA reductase, scavenges free radicals and inhibits lipid peroxidation in rat liver microsomes. Eur. J. Pharmacol. 1998, 361:143-149.
178. Schupp N., Schmid U., Heidland A., Stopper H. Rosuvastatin protects against oxidative stress and DNA damage in vitro via up-regulation of glutathione synthesis. Atherosclerosis 2008, 199(2):278-287.
179. Harangi M., Seres I., Varga Z., Emri G., Szilvássy Z., Paragh G., et al. Atorvastatin effect on high-density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur. J. Clin. Pharmacol. 2004, 60(10):685-691.
180. Mahmoudi M., Gorenne I., Mercer J., Figg N., Littlewood T., Bennett M. Statins use a novel Nijmegen breakage syndrome-1-dependent pathway to accelerate DNA repair in vascular smooth muscle cells. Circ. Res. 2008, 103(7):717-725.
181. Ostrau C., Hulsenbeck J., Herzog M., Schad A., Torzewski M., Lackner K.J., Fritz G. Lovastatin attenuates ionizing radiation-induced normal tissue damage in vivo. Radiother. Oncol. 2009, 92:492-499.
182. Nuebel T., Damrot J., Roos W.P., Kaina B., Fritz G. Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin. Cancer Res. 2006, 12:933-939.
183. Manfredini V., Biancini G.B., Vanzin C.S., Dal Vesco A.M., Cipriani F., Biasi L., et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients. Cell Biochem. Funct. 2010, 28(5):360-366.
184. Pernice F., Floccari F., Caccamo C., Belghity N., Mantuano S., Pacilè M.E. Chromosomal damage and atherosclerosis. A protective effect from simvastatin. Eur. J. Pharmacol. 2006, 532:223-229.
185. Herbert K.E., Mistry Y., Hastings R., Poolman T., Niklason L., Williams B. Angiotensin II-mediated oxidative DNA damage accelerates cellular senescence in cultured human vascular smooth muscle cells via telomere-dependent and independent pathways. Circ. Res. 2008, 102:201-208.
186. Oeseburg H., Iusuf D., van der Harst P., van Gilst W.H., Henning R.H., Roks A.J. Bradykinin protects against oxidative stress-induced endothelial cell senescence. Hypertension 2009, 53:417-422.
187. Khaper N., Singal P.K. Modulation of oxidative stress by a selective inhibition of angiotensin II type 1 receptors in MI rats. J. Am. Coll. Cardiol. 2001, 37:1461-1466.
188. Pechter U., Aunapuu M., Riispere Z., Vihalemm T., Kullissaar T., Zilmer K., et al. Oxidative stress status in kidney tissue after losartan and atenolol treatment in experimental renal failure. Nephron Exp. Nephrol. 2004, 97(2):e33-e37.
189. Fiordaliso F., Cuccovillo I., Bianchi R., Bai A., Doni M., Salio M., et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin induced diabetes. Life Sci. 2006, 79:121-129.